论文部分内容阅读
目的观察FOLFIRI方案联合西妥昔单抗新辅助化疗大肠癌肝转移的临床疗效。方法选取收治大肠癌肝转移患者40例,随机分为观察组和治疗组各20例,观察组给予FOLFIRI方案联合西妥昔单抗辅助治疗,对照组仅给予FOLFIRI方案治疗,比较肝脏R0切除情况,以治疗后肝脏CT及肿瘤标记物评价疗效。结果观察组总有效率(RR)为60.0%,疾病控制率(DCR)为95.0%;对照组总有效率(RR)为30.0%,疾病控制率(DCR)为60.0%,差异具有统计学意义(P<0.05)。观察组肿瘤标记物CEA下降程度高于对照组(P<0.05)。观察组肝转移灶R0切除率为85.0%;对照组肝转移灶R0切除率为65.0%,两组差异显著(P<0.05)。观察组皮疹发生率为75%;对照组未出现。结论FOLFIRI方案联合西妥昔单抗新辅助化疗大肠癌肝转移,能够提高原发灶及转移灶R0切除率,对减少根治术后肿瘤的转移和复发具有重要意义。
Objective To observe the clinical efficacy of FOLFIRI regimen combined with neoadjuvant chemotherapy with cetuximab for colorectal cancer liver metastases. Methods Forty patients undergoing colorectal liver metastasis were randomly divided into two groups: observation group and treatment group (20 cases each). The observation group received FOLFIRI regimen combined with cetuximab adjuvant therapy, and the control group received only FOLFIRI regimen. The comparison of liver R0 resection was performed. , To evaluate the curative effect of liver CT and tumor markers after treatment. Results The total effective rate (RR) of the observation group was 60.0%, and the disease control rate (DCR) was 95.0%. The total effective rate (RR) of the control group was 30.0% and the disease control rate (DCR) was 60.0%. The difference was statistically significant. (P<0.05). The CEA of the tumor markers in the observation group decreased more than that in the control group (P<0.05). The R0 resection rate of the liver metastases in the observation group was 85.0%, and the R0 resection rate of the liver metastases in the control group was 65.0%. There was a significant difference between the two groups (P<0.05). The incidence of rash in the observation group was 75%; the control group did not appear. Conclusion FOLFIRI regimen combined with neoadjuvant chemoinfusion of cetuximab for colorectal cancer liver metastasis can increase the R0 resection rate of primary and metastatic lesions and is of great significance in reducing the metastasis and recurrence of metastatic tumors after radical resection.